Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab
CSET N°2017/2536
Phase 2 small_molecule active
Quick answer
Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab for Adjuvant therapy after salvage surgery of high risk recurrent head and neck squamous cell carcinoma (HNSCC) is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Adjuvant therapy after salvage surgery of high risk recurrent head and neck squamous cell carcinoma (HNSCC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active